Slide 1: 4Q & FY 2022 Results Conference Call and Webcast
4Q & FY 2022 Results Conference Call and Webcast March 7, 2023 Nasdaq: ZYME | zymeworks.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange A
Slide 3: Chris Astle, Ph.D. Senior Vice President & Chief Financial Officer
Chris Astle, Ph.D. Senior Vice President & Chief Financial Officer Making a Meaningful Difference 3
Slide 4: Full Year 2022 Financial Results
Full Year 2022 Financial Results In millions USD Full Year 2021 Full Year 2022 • Revenue in 2022 primarily driven by $375MM in upfront payments and approximately $24MM in zanidatamab related Revenue $26.7 $412.5 reimbursements • R&D Expense increase primarily driven by higher manufacturing and clini
Slide 5: Five by Five: Delivering on a Focused Early Research and Development Strategy
Five by Five: Delivering on a Focused Early Research and Development Strategy Early Research and Development Pipeline ZW191 Folate Receptor-⍺ Targeted Topoisomerase 1 Inhibitor • Focused strategy to have five novel preclinical product candidates in Antibody Drug Conjugate clinical studies by 2027 In
Slide 6: Zanidatamab Zovodotin: Focused and Strategic Development Path
Zanidatamab Zovodotin: Focused and Strategic Development Path Zanidatamab zovodotin has shown single-agent activity in multiple tumor types with a differentiated tolerability profile amongst other HER2-targeted ADCs and has multiple pathways for DIFFERENTIATED STRATEGY development Planned Phase 2 St
Slide 7: Zanidatamab: Recent Data Continues to Support Potential Best-in-Class HER2-targeted therapy in BTC and GEA
Zanidatamab: Recent Data Continues to Support Potential Best-in-Class HER2-targeted therapy in BTC and GEA HERIZON-BTC-01 Updated Phase 2 data in 1L GEA December 2022 Top-line data ASCO Gastrointestinal Cancers Symposium Data Presentation • cORR of 41.3% [95% CI: 30.4, 52.8] • 84% [95% CI: 68, 93] o
Slide 8: Enterprise Value Framework
Enterprise Value Framework Our Strategy Zymeworks is well-positioned to build upon our key priorities and enhance shareholder value Global1 Zanidatamab Zanidatamab through focusing on our Enterprise Value Collaboration with Collaboration with Framework Jazz Pharmaceuticals BeiGene in APAC Zanidatama
Slide 9: Q&A
Q&A Kenneth Galbraith Chair and CEO Neil Klompas President and COO Chris Astle, Ph.D. SVP and CFO Paul Moore, Ph.D. CSO Making a Meaningful Difference 9